Syndax Pharmaceuticals, Inc.
Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Abstract:

Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.